
Bristol-Myers Squibb Co BMY.N:
BRISTOL MYERS SQUIBB ANNOUNCES TOPLINE RESULTS FROM PHASE 3 INDEPENDENCE TRIAL FOR REBLOZYL® (LUSPATERCEPT-AAMT) IN ADULT PATIENTS WITH MYELOFIBROSIS-ASSOCIATED ANEMIA
BRISTOL-MYERS SQUIBB CO - REBLOZYL DID NOT MEET PRIMARY ENDPOINT IN PHASE 3 TRIAL
BRISTOL-MYERS SQUIBB CO - SECONDARY MEASURES SHOWED BENEFITS FAVORING REBLOZYL
BRISTOL-MYERS SQUIBB CO - BRISTOL MYERS SQUIBB TO DISCUSS MARKETING APPLICATIONS WITH FDA AND EMA